Lecture 33 - Rotavirus Pathogenesis and Disease Flashcards
How was rotavirus discovered?
Reovirus-like particles in intestinal epithelial cells
Infectious agent that causes most severe diarrhoea and dehydration than others
Rotavirus
Annual deathrate of rotavirus in developing countries
1/200
Total annual deaths from rotavirus in 2008
500, 000
Effect of rotavirus vaccination
45% reduction in rotavirus hospitalisations since 2006
Other disease manifestations of rotavirus 1 2 3 4
1) Low-level viremia common
2) ~4% develop CNS disease (encephalitis)
3) Occasional liver involvement
4) Autoimmune. Type 1 DM, coeliac disease
Rotavirus family
Reoviridae
Rotavirus genome
Segmented, dsDNA (11 segments)
Rotavirus capsid symmetry
Icosahedral
Rotavirus core protein
VP2
Rotavirus VP4
Trypsin-cleaved into VP5 and VP8.
VP5 and VP8 are receptor ligands
Rotavirus inner capsid protein
VP6
Rotavirus outer capsid proteins
VP4, VP7
Rotavirus protein important in serotyping
VP6
Proportion of rotovirus proteins that are structural
~1/2
How can individual rotavirus isolates be distinguished?
Electropherotyping
Rotavirus gene arrangement on genome
Each segment encodes a single protein, except for one segment (VP1, 2, 3, 4, 6, 7, NSP1-5)
Laboratory diagnosis of rotavirus 1 2 3 4 5 6 7
1) ELISA with antibodies against group antigens (EG: VP6)
2) RT-PCR
3) Electron microscopy
4) Electropherotyping
6) Seroconversion
7) IgA conversion in stools
Aspect of rotavirus infection that leads to diarrhoea
Destruction of absorptive capacity of vili
NSP4 (viral toxin)
What are rotavirus neutralising antibodies directed against?
Either outer capsid protein (VP4 or VP7)
VP4 = P serotype
VP7 = G serotype
Serotyping of stool rotaviruses
ELISA to VP4 or VP7 give serotypes
Genotyping of stool rotaviruses
Nested-set RT-PCR
Most-common rotavirus G serotypes in humans
VP7 type 1, 2, 3, 4, 9
Number of G types in humans
Over 27
Most common P serotypes in humans
VP4 1A8, 1B6, 2A4
How is serotype diversity generated in rotavirus?
Genome reassortment
Do VP4 and VP7 serotypes reassort dependently?
No. They reassort independently
Multiplicity of infection
Proportion of infectious viral particles to a single cell
Is affinity of a viral ligand/receptor interaction normally high?
No. Normally low, but increases in avidity due to multivalent interactions with one or more receptors
Rotavirus binding and entry to host cell
1)
2)
3)
1) VP4 cleaved by trypsin to VP5 and VP8
2) Initial attachment of VP8 to glycans (sialic acids or histo-blood group antigens)
3) Binding and entry via endocytosis. Mediated by VP5 and VP7 interactions with integrins. Complexes of glycans and/or integrins in lipid rafts may be involved
Sialidase-sensitive rotaviruses
Attach to terminal sialic acids.
These can be cleaved by sialidase.
Sialidase-resistant rotaviruses
Attach to branched (internal) sialic acids.
These normally can’t be cleaved by sialidase
Main human sialidase-resistant rotaviruses
Wa, RV-3
Human rotavirus that attaches to A-type histo-blood group antigen
RV-3
Two groups of sialidase-sensitive rotaviruses
1) Acetyl.
2) Glycolyl
Based on group attached to terminal sialic acid
What do human rotaviruses Wa and RV-3 bind to?
Branched sialic acid on ganglioside GM1
Gangliosides
Glycolipids
What on a rotavirus determines the glycan class that it binds to?
VP8 architecture
VP4 conformation change in call entry
Hydrophobic domain is revealed upon attachment, fuses with cell membrane
Methods of defining viral receptor specificity 1) 2) 3) 4) 5)
1) Receptor ligand (EG: anti-receptor antibody) blocks virus attachment
2) Structural studies of receptor-ligand complexes
3) Cell expression of DNA for receptor confers susceptibility
4) Glycan array analysis of virus receptor protein-glycan complexes
5) Bioinformatics - Presence of amino acid sequence in a virus protein
VP5, VP7 integrin ligands
Type I collegen, fibrinogen
VP5 integrin natural ligand
Integrin alpha2beta1 in type I collagen
VP7 integrin natural ligand
Integrin alphaXbeta2 in fibrinogen
What determines rotavirus ability to use integrins as cell receptors
VP4 serotype.
Independent of glycan, ganglioside usage
Alpha2beta1 integrin in rotavirus infection
Rotavirus cellular receptor. Bound by VP4
AlphaXbeta2 integrin in rotavirus infection
Rotavirus coreceptor. Bound by VP7
Motif in VP4 that binds to alpha2beta1 integrin
DGE
Relationship between type 1 diabetes and rotavirus infection
1
2
3
1) Correlation between rotavirus seroconversion and development of type 1 diabetes.
2) If infection occurs at 5 days - Increased Treg production, reduction in diabetes
3) Infection at 12 weeks - Increased diabetes incidence.
Effect of rotavirus infection at 5 days on non-obese diabetic mice
1) Diarrhoea, extra-intestinal spread
2) Reduction in diabetes rate of development
Effect of rotavirus infection at 12 weeks on non-obese diabetic mice
1
2
3
1) No diarrhoea.
2) Virus found extra-intestinally in mesentaric, pancreatic lymph nodes only
3) Increased rate of diabetes development
Proposed mechanism of diabetes acceleration by rotavirus in NOD mice 1 2 3 4
1) Plasmacytoid DCs activated by rotavirus
2) Viral RNA triggers TLR, pDCs release IFN1
3) T-, B-cells activated by IFN1.
4) Autoreactive CD8+ T cell presented autoantigen, begins killing beta cells in pancreas
Proportion of infants infected by rotavirus by one year in developing and developed nations
80% in developing, 65% in developed
Aim of rotavirus vaccines
Prevent severe gastro in first two years of life
Where do rotavirus vaccines need to be administered?
Mucosally.
Secreted IgA in gut at time of rotavirus infection correlated with best outcomes in animals
Most effective way to stimulate mucosal immune response in GIT against rotavirus
Infection involving local site
Rotavirus vaccines
1
2
3
1) Heterologous lamb rotavirus
2) Partially heterologous reassortment rotaviruses - Rotashield, Rotateq
3) Culture-adapted rotavirus - Rotarix
Rotashield
1
2
1) Partially-heterologous reassortment rotavirus
2) Rhesus rotavirus (RRV) with human rotavirus VP7. Seotypes G1, G2, G4
3) Quadravalent, live-attenuated vaccine
Rotateq
1
2
1) Partially-heterologous reassortment rotavirus
2) Bovine rotavirus WC3 with culture-adapted human rotavirus P1 VP4 and G1-4 VP7
Problem with Rotashield
Strong correlation between Rotashield and intussusception in infants (1 excess case per 20,000 infants vaccinated)
Relationship between Rotashield and intussusception
1) Under 1 excess case per 20,000 infants vaccinated
2) Vaccination at 4-6 months of age associated with increased risk. Better to vaccinate younger
Rotarix 1 2 3 4
1) Monovalent, live-attenuated vaccine
2) Human G1 isolate with most-common VP4
3) 85-100% efficacy vs severe disease
4) 75% efficacy against any rotavirus disease
Rotavirus strain that Rotarix is less-effective against
G2P4
Rotateq 1 2 3 4
1) Pentavalent, human-bovine reassortment vaccine
2) Has most-common human VP4 (P1A8) and VP7 (G types 1-4)
3) 98% efficacy vs severe disease
4) 41-92% efficacy against any rotavirus disease
Rotateq efficacy under 2 years in Australia
1
2
1) 93% decline in rotavirus hospitalisations
2) 53-65% decline in rotavirus notifications
Rotarix efficacy under 2 years in Australia
75% decline in rotavirus hospitalisations (93% in infants under 1 year)